BioNTech SE (BNTX) BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
BioNTech SE NASDAQ:BNTX Healthcare · Biotechnology
Mkt Cap $22.15B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 3
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
This is a paid third-party commentary, not a BioNTech press release; it recaps Merck and Moderna's positive Phase 3 INTerpath-001 results for intismeran autogene in melanoma, where the KEYTRUDA combination cut recurrence or death risk by 42%.
For BioNTech, the article re-reports its August 2026 decision, with Genentech, to terminate the Phase 2 trial of autogene cevumeran as adjuvant monotherapy in colorectal cancer after a DSMB-identified numerical OS imbalance; the pancreatic cancer trial continues.
The release's true subject is a promotional push for MindWalk Holdings (HYFT) and its LensAI platform, and the disclaimer discloses paid compensation and a conflict of interest. No new BioNTech information is disclosed; treat as low-signal promotional content.
• 6d ago AI analysis › Press Release ● Major ⚠ 4
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
BioNTech and DualityBio announced that the DYNASTY-Breast02 Phase 3 trial of trastuzumab pamirtecan (BNT323/DB-1303) met its primary endpoint, showing a statistically significant but modest PFS improvement versus chemotherapy in HR+/HER2-low metastatic breast cancer.
The signal is clouded: interim OS data were not mature, and a higher rate of interstitial lung disease was reported versus prior trials, with severe and fatal events in a small proportion of patients.
The companies themselves caution the potential patient benefit would be limited in the current treatment landscape and will discuss the data before determining next steps — a negative read for the asset's commercial prospects in this indication.
• 6d ago AI analysis › Press Release ● Major
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
globenewswire.com • 8d ago Press Release ⚠ 2
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
BioNTech announced a clinical trial collaboration and supply agreement with Gilead Sciences to evaluate pumitamig in combination with the TROP2-directed ADC sacituzumab govitecan (Trodelvy) as first-line treatment for PD-L1 low or negative metastatic triple-negative breast cancer.
The global Phase 3 ROSETTA Breast-01 trial will be adapted, pending regulatory approval, to replace chemotherapy with sacituzumab govitecan, reflecting the evolving standard of care; BioNTech remains trial sponsor and Gilead will supply the ADC.
Pumitamig is jointly developed with Bristol Myers Squibb and is already in seven ongoing global Phase 3 trials — this becomes the first Phase 3 test of pumitamig in combination with an ADC, broadening its pivotal-stage development.
• 10d ago AI analysis › Press Release
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
BioNTech will report third quarter 2026 financial results on Tuesday, November 3, 2026, followed by a conference call and webcast at 8:00 a.m. ET.
The release contains no financial results or guidance; it is a scheduling notice with dial-in and webcast access details.
The company's late-stage oncology pipeline spans immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies, with partners including Pfizer, Genentech, and Genmab.
• 12d ago AI analysis › Press Release ⚠ 2
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
BioNTech will present 16 abstracts across ten tumor types at the ESMO 2026 Congress in Madrid, October 23-27, 2026, headlined by late-breaking oral data for pumitamig plus docetaxel in second-line metastatic NSCLC.
First global Phase 2 results for the novel-novel combination of pumitamig with the B7-H3 ADC elfetabart drozuntecan showed encouraging preliminary antitumor activity across multiple advanced solid tumors with a manageable safety profile.
Pumitamig, a PD-L1xVEGF-A bispecific being co-developed with Bristol Myers Squibb, is positioned as a potential combination backbone across tumor types, including brain-metastasis settings in SCLC and TNBC.
BioNTech has 13 ongoing Phase 3 trials in oncology; this is a data-calendar announcement, not new registrational efficacy data.
• 13d ago AI analysis › Press Release ● Major ⚠ 3
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
BioNTech's AHEAD-MERIT Phase 2/3 trial of BNT113 plus pembrolizumab missed its first dual primary endpoint of progression-free survival versus pembrolizumab alone in first-line metastatic HPV16+ head and neck cancer.
The IDMC recommended the trial continue to the second dual primary endpoint of overall survival; under the pre-specified design, a statistically significant OS improvement would still constitute a positive trial outcome despite the PFS miss.
BNT113 is a key pillar of BioNTech's oncology strategy and holds FDA Fast Track Designation (January 2026); there are currently no approved HPV-targeted cancer treatments, so the OS readout is the remaining path for the program.
• 19d ago AI analysis › Press Release ⚠ 3
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
This GlobeNewswire item is paid third-party market commentary from MarketNewsUpdates, not an issuer disclosure; BioNTech appears only in a list of 'active' antiviral names and in a recycled reference to the FDA approval of COMIRNATY XFG that was announced the prior month.
The bulk of the piece promotes NanoViricides' Phase II trial of oral NV-387 against the Bundibugyo Ebola outbreak in the DRC, which has reached 7,022 confirmed cases and a roughly 48% crude fatality rate; the publisher discloses $2,500 in compensation for the NanoViricides coverage.
Cited market figures include a $42.3 billion antiviral market in 2025 growing to a projected $57.8 billion by 2034. No new information about BioNTech's pipeline, operations, or financials is presented, so this is promotional noise for BNTX.
• 1mo ago AI analysis › Press Release ● Major ⚠ 3
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
BioNTech and OncoC4 reported the first median overall survival data from stage 1 of the Phase 3 PRESERVE-003 trial: gotistobart monotherapy achieved 18.5 months median OS versus 10.0 months for standard-of-care docetaxel in previously treated squamous NSCLC (HR 0.56; nominal p=0.0295), nearly doubling survival.
The readout covered 87 randomized patients with a July 17, 2026 data cut-off and 25.4 months median follow-up, with comparable safety between arms — grade ≥3 treatment-related adverse events occurred in 44.4% of gotistobart patients versus 48.8% on docetaxel.
The pivotal stage 2 portion of PRESERVE-003 is ongoing at more than 160 sites globally; confirmation of this survival benefit in the pivotal stage is the required next step before the standard of care in this indication changes.
• 1mo ago AI analysis › Press Release ● Major
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Pfizer and BioNTech received FDA approval for their 2026-2027 XFG-adapted COVID-19 vaccine for adults 65 and older and high-risk individuals aged 5 through 64.
Shipping of the updated formula begins immediately to ensure availability in pharmacies, hospitals, and clinics across the U.S. for the coming days.
The approval is based on cumulative evidence showing the vaccine generates strong immune responses against currently circulating variants, including XFG and its sub-lineages.
• 2mo ago AI analysis › Press Release
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
BioNTech will present new clinical data at the IASLC 2026 World Conference on Lung Cancer, including first data on a novel-novel combination of pumitamig and elfetabart drozuntecan in advanced or metastatic lung cancer.
The company's lung cancer program spans 16 ongoing clinical trials, including five Phase 3 studies and two novel-novel combination trials, with updated overall survival data for gotistobart from the PRESERVE-003 Phase 3 trial.
Key collaborations include Bristol Myers Squibb on pumitamig, Duality Biologics on elfetabart drozuntecan, and OncoC4 on gotistobart.
• 2mo ago AI analysis › Press Release ● Major ⚠ 3
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
BioNTech reported Q2 2026 revenue of €105.6 million, down from €260.8 million in the prior year, and revised its full-year revenue guidance to €1.6-1.9 billion due to softer global COVID-19 vaccine demand.
Despite the revenue shortfall, the company advanced its oncology pipeline with the initiation of six pivotal trials, including five for pumitamig, and maintained a strong balance sheet with €16.6 billion in cash and equivalents.
In a major corporate governance shift, BioNTech appointed Guido Oelkers, Ph.D., as the new CEO to succeed founder Prof. Ugur Sahin by February 2027, while actively repurchasing $151.6 million of shares under its authorization program.
• 2mo ago AI analysis › Press Release ● Major ⚠ 1
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
BioNTech announced the appointment of Guido Oelkers, Ph.D., as its new Chief Executive Officer to succeed founder Prof. Ugur Sahin, effective no later than February 1, 2027.
Oelkers joins from Swedish Orphan Biovitrum AB (Sobi), where he served as CEO since 2017 and quadrupled revenues, bringing extensive commercial scaling experience to support BioNTech's transition to a multi-product company.
Co-founders Prof. Ugur Sahin and Chief Medical Officer Prof. Özlem Türeci will depart to lead a new independent company, with Sahin remaining actively involved to ensure a smooth leadership handover.
• 2mo ago AI analysis › Press Release ⚠ 1
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
The European Commission has granted marketing authorization for the Pfizer and BioNTech 2026-2027 COVID-19 vaccine formula targeting the XFG variant for individuals 6 months and older.
The authorization covers all 27 EU Member States as well as Iceland, Liechtenstein, and Norway, following a recommendation from the EMA's Emergency Task Force.
Manufacturing has been initiated at risk, with shipping expected to begin soon to ensure availability for the upcoming respiratory disease season.
• 3mo ago AI analysis › Press Release
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
BioNTech announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026.
The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a corporate update.
A replay of the webcast will be made available on the company's website for 30 days following the call.
• 3mo ago AI analysis › Press Release ● Major
Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
globenewswire.com • 5mo ago Press Release ● Major
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
globenewswire.com • 5mo ago Press Release
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
globenewswire.com • 5mo ago Press Release
BioNTech Announces New ADS Repurchase Program
globenewswire.com • 5mo ago Press Release
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
globenewswire.com • 5mo ago Press Release
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
globenewswire.com • 6mo ago 
